Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Cancer PHGKB

Specific PHGKB|Cancer|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Effective August 1, 2024, this database will be discontinued. All content will remain searchable and be preserved online for historical purposes only until 2029.

Last Posted: Jul 24, 2024
spot light Spotlight

Advancing Genomic Cancer Medicine in Rural and Underserved States
(Posted Jul 22, 2024 10AM)

From the article: "In the evolving landscape of oncology, the integration of powerful genomic technologies into practice has ushered in a new era of precision cancer medicine. Complex genomic information such as mutational analyses, transcriptional signatures, and polygenic risk scores have become key diagnostics guiding therapeutic decisions and management of inherited cancer risk. However, the expertise to interpret these data for clinical decision-making remains constrained and is a significant challenge for community oncologists, especially those in rural regions and in medically underserved areas. While physical access to these tests is readily available, poor access to interpretive expertise has become the key limiting factor. "

Benefits for children with suspected cancer from routine whole-genome sequencing
(Posted Jul 18, 2024 8AM)

From the abstract: " Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n=152 from a hematology center, n?=?130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases."

A roadmap for affordable genetic medicines
(Posted Jul 18, 2024 8AM)

From the abstract: "Nineteen genetic therapies have been approved by the U.S. Food and Drug Administration (FDA) to date, a number that now includes the first CRISPR genome editing therapy for sickle cell disease, CASGEVY (exagamglogene autotemcel). This extraordinary milestone is widely celebrated because of the promise for future genome editing treatments of previously intractable genetic disorders and cancers. At the same time, such genetic therapies are the most expensive drugs on the market, with list prices exceeding $4 million per patient. "

BRCA1 and friends 30 years on
(Posted Jul 08, 2024 8AM)

From the abstract: "With the benefit of hindsight, recognition of the cancer susceptibility gene BRCA1 and its later cloning were defining moments for breast and ovarian cancer genetics that should be celebrated. "


news Latest News and Publications
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma. External Web Site Icon
Pinto A, et al. British journal of haematology 2024 0 0.
Genetic predisposition to milder forms of COVID-19 may provide some resilience to head and neck cancers. External Web Site Icon
Han Boxuan, et al. Frontiers in oncology 2024 0 0. 1384061
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody. External Web Site Icon
Maruyama Shuhei, et al. BMC infectious diseases 2024 0 0. (1) 715
IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy. External Web Site Icon
Jolly Kevon J, et al. Advances in pharmacology (San Diego, Calif.) 2024 0 0. 247-288
Identifying risk factors for severe omicron infection in allogeneic hematopoietic stem cell transplant recipients with hematologic malignancies. External Web Site Icon
Li Zhihui, et al. Cancer reports (Hoboken, N.J.) 2024 0 0. (6) e2103
Report of the sixth meeting of the European Consortium 'Care for CMMRD' (CCMMRD), Paris, France, November 16th 2022. External Web Site Icon
Guerrini-Rousseau Léa, et al. Familial cancer 2024 0 0.
Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study. External Web Site Icon
Freeman Jincong Q, et al. JMIR cancer 2024 0 0. e55438
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial. External Web Site Icon
Griffin David W J, et al. Trials 2024 0 0. (1) 485
Deep IDA: a deep learning approach for integrative discriminant analysis of multi-omics data with feature ranking-an application to COVID-19. External Web Site Icon
Wang Jiuzhou, et al. Bioinformatics advances 2024 0 0. (1) vbae060
Household income unequally affects genetic susceptibility to pulmonary diseases: evidence from bidirectional Mendelian randomization study. External Web Site Icon
Xu Hongfa, et al. Frontiers in medicine 2024 0 0. 1279697

More

About Cancer PHGKB

Cancer PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to cancer...more

Content Summary

Common Type

Quick Links


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP